Innovator’s Pitch Challenge

Vote for Me

Interested in Connecting? Please contact:
Alon Singer
CEO
asinger@helixbind.com

Message the company or request a 1:1 meeting here

HelixBind is developing a diagnostic platform to revolutionize care for invasive infections such as sepsis. The company’s proprietary RaPID technology provides characterization of bloodstream infections at single CFUs/ml sensitivity, direct from blood (culture-free). The platform is easy to use and appropriate for hospitals of any size, provides results within three hours, rather than days as is common today, and detects infections missed by today’s current diagnostic standards. Having completed multiple clinical studies proving product performance, HelixBind has completed a pre-sub with the FDA and is scaling manufacturing in preparation for clinical trials.

Pitch Video

Slide Deck

Executive Summary